VaccineFifteen years following the approval of the firsthuman papillomavirus(HPV)vaccine, cervical cancer continues to be a significant source of morbidity and mortality among women in low-resource settings. It is the second-leading cause of cancer-related deaths in women globally and the leading ...
More information:Yenan Zhu et al, Reimbursement for HPV Vaccine Cost in the Private Sector: A Comparison Across Specialties,The Annals of Family Medicine(2023).
“Family physicians, who are so critical and important, especially in rural areas where not all patients have access to pediatricians, are not receiving adequate reimbursement for the HPV vaccine, which is sort of a disincentive for them to offer this critical cancer-preventive vaccine,” Sonawane...
How can we achieve HPV control in Europe? In countries with a lower coverage gender-neutral vaccination is an even more important option. The quadrivalent vaccine has been demonstrated to be highly ... EA Joura,S Pils - 《Future Virology》 被引量: 7发表: 2015年 ...
Screening costs were higher for clinics at $21.84, compared to $17.48 for CHCs. In contrast, CHCs had higher outreach costs ($3.34 vs. $0.17). After modeling a reduction in staffing, clinic per-screening costs ($25.69) were approximately equivalent to CHCs. Conclusions HPV-based cervical ...
Human papillomavirus (HPV) infection has been shown to be a major risk factor for cervical cancer. Vaccines against HPV-16 and HPV-18 are highly effective in preventing type-specific HPV infections and related cervical lesions. There is, however, limited
adherence to cervical screening, costs or health utilities for various conditions, parameters related to the natural history of disease, discount rate, etc; we also examined the impact of starting vaccination at different ages on the cost-effectiveness ratio for HPV vaccine in sensitivity analysis. ...
The CDC recommends HPV vaccination for girls and boys ages 11 to 12. The vaccine can also be given to anyone 26 and under who has not been adequately vaccinated and children as young as 9, if needed. Some people up to age 45 are also eligible.2 ...
Health impact and cost-effectiveness of implementing gender-neutral vaccination with the 9-valent HPV vaccine in Hong Kong In the base case analysis, the ICER was $248,354 per QALY for routine GNV. As compared with FOV, routine GNV fell below the cost-effectiveness ... T Cheung,SY Cheng,...
adherence to cervical screening, costs or health utilities for various conditions, parameters related to the natural history of disease, discount rate, etc; we also examined the impact of starting vaccination at different ages on the cost-effectiveness ratio for HPV vaccine in sensitivity analysis. ...